bromperidol

Trade name: tesoprel

Small moleculeexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1

Earliest trial started Nov 1, 2014 (NCT02307396)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1
Mol. weight
420.32 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-(4-(4-bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
  • azurene
  • bromoperidol
  • bromoperidol
  • bromperidol
  • bromperidol
  • bromperidol
  • bromperidol
  • bromperidol
  • bromperidol
  • bromperidol
  • bromperidol, 82br-labeled
  • bromperidol hcl
  • bromperidol hydrochloride
  • bromperidol hydrochloride
  • bromperidol hydrochloride
  • bromperidol hydrochloride
  • bromperidol hydrochloride
  • c-c 2489-21
  • impromen
  • impromen
  • impromen
  • impromen
  • r 11,333
  • r-11333
  • r-11333
  • tesoprel
  • tesoprel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02374567Phase 3Jan 1, 2015Gottfried Wilhelm Leibniz Universität Hannover
NCT02307396Phase 4Nov 1, 2014Technical University of Munich
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1112015
Technical University of MunichAcademic/Hospital1112014
2 organizations
Page 1 / 1